Markets open

Biogen Inc.

BIIB · Nasdaq

Analyst Consensus

Buy

35 analysts

$209

Current

—

Low

$239

Average

—

High

Average target implies +14.20% versus the current price.

The ratings synthesis for BIIB has not been generated yet.

Rating Actions

No individual rating actions have been captured for BIIByet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BMO CAPITAL MKT

BTIG

CANACCORD GENUI

CANTOR FITZGERA

CO FORECST

EVERCORE ISI

GOLDMAN SACHS

GUGGENHEIM SEC.

H C WAINWRIGHT

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MIZUHO SECURITI

MORGAN STANLEY

NEEDHAM & CO.

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

ROTHSCHILD REDB

SCOTIABANK

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

UBS

WEDBUSH SECURIT

WELLS FARGO SEC

WILLIAM BLAIR

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: BIIB
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: Nasdaq

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.